Nammi Therapeutics | Next Stage in Immuno-Oncology

Our Mission

The Nammi Rationale

Nammi Therapeutics scientists believe that the key challenges facing immunotherapies for cancer treatment are:

• Redundancy of regulatory pathways: Immune functions are tightly controlled by multiple overlapping mechanisms, requiring intervention in several processes to stimulate and maintain an effective anti-tumor response.
• Systemic toxicities: Potent immune modulating therapies often cause severe, sometimes fatal, side effects when administered systemically.
• High development costs: Determining optimal combinations through large clinical trials is time-consuming and expensive.

Our Solution

To overcome these challenges, Nammi has developed three key criteria for its immunotherapies:

Multi-functional modulation: Designed to influence multiple immune functions across different cell types.
Site-specific activation: Immune agents remain inactive in circulation and are activated only within the tumor microenvironment.
Tumor-selective targeting: Mechanisms ensure therapeutics are delivered and concentrated at the tumor site.

World-Class Scientific Team

Nammi has assembled a world-class scientific team with deep expertise in oncology, immunology, and drug development. Our leaders have pioneered key technologies in immuno-oncology and have led discovery and development teams at major pharmaceutical companies including Novartis and Astellas.

Several of our directors have founded successful biotech ventures that resulted in FDA-approved therapies and strong returns for investors. This blend of academic excellence, industry experience, and entrepreneurial success positions Nammi to accelerate the development of transformative cancer treatments.

Innovative Platform Technologies

Nammi has developed two complementary platform technologies that enable selective targeting of immunotherapies to tumors, maximizing efficacy while minimizing off-target effects.

Masked ImmunoCytokines (MICs)

A tumor antigen-targeting antibody fused to a masked cytokine. The cytokine remains inactive in circulation and is selectively activated within the tumor microenvironment through protease cleavage of the masking peptide.

• Enables direct anti-tumor killing
• Initiates robust immune response
• Minimizes systemic exposure
• Tumor-specific activation

Nammisomes

Prodrugs of immune modulators formulated as combinations in lipid-based nanoparticles. These solid lipid nanoparticles deliver payloads selectively to the tumor site.

• Co-delivery of multiple agents
• Enhanced tumor accumulation
• Controlled release kinetics
• Reduced systemic toxicity

Our Product Pipeline

Nammi Therapeutics is advancing a portfolio of tumor-targeted immunotherapies leveraging our proprietary platform technologies.

QXL138AM

Masked ImmunoCytokine

An anti-CD138 targeting antibody fused to IFNα2 cytokine, with a masking peptide attached via a protease-cleavable linker. Activated selectively in the tumor microenvironment.

Target: CD138+ tumors (e.g., multiple myeloma)
Mechanism: Tumor-targeted IFNα2 delivery
Activation: Protease-mediated unmasking
Stage: Preclinical development

SLNP-IC1

Nammisome

A solid lipid nanoparticle incorporating a doxorubicin prodrug (IC1). Designed for selective delivery to tumor tissue with reduced cardiotoxicity.

Active Agent: Doxorubicin prodrug
Delivery: Tumor-targeted nanoparticles
Advantage: Lower systemic exposure
Stage: Preclinical optimization

NTI-121

Nammisome

A solid lipid nanoparticle co-formulated with a doxorubicin prodrug (IC1) and a Toll-like Receptor 7 agonist prodrug (TR12), enabling synergistic anti-tumor immunity.

Agents: IC1 + TR12 prodrugs
Mechanism: Chemo-immunotherapy combination
Target: Solid tumors
Stage: Lead optimization

NTI-205

Masked ImmunoCytokine

Preclinical candidate targeting HER2+ tumors with masked IL-12 fusion. Designed to stimulate potent T-cell responses locally.

Target: HER2+ cancers
Cytokine: IL-12 (masked)
Linker: MMP-cleavable
Stage: Candidate selection

SLNP-PD1

Nammisome

Nanoparticle formulation of a PD-1 inhibitor prodrug for intratumoral release, aiming to overcome resistance to systemic checkpoint inhibitors.

Agent: PD-1 inhibitor prodrug
Goal: Local immune checkpoint blockade
Combination: With MICs or chemotherapy
Stage: Early discovery

QXL150GM

Masked ImmunoCytokine

Anti-PSMA antibody fused to masked GM-CSF for activation of dendritic cells specifically in prostate tumor microenvironments.

Target: PSMA+ prostate cancer
Function: Dendritic cell recruitment
Activation: Tumor protease-dependent
Stage: Target validation

NTI-300

Nammisome

Triple-combination Nammisome containing doxorubicin, a STING agonist, and an IDO inhibitor prodrug for broad immune activation.

Agents: Chemo + STING + IDO
Goal: Overcome immunosuppressive TME
Delivery: Co-encapsulated in lipid NP
Stage: Formulation screening

QXL110IF

Masked ImmunoCytokine

Anti-EGFR antibody fused to masked interferon gamma, designed to enhance antigen presentation and MHC expression in epithelial tumors.

Target: EGFR+ carcinomas
Cytokine: IFN-γ (masked)
Effect: Enhanced tumor immunogenicity
Stage: Preclinical testing

Development Pipeline

Product	Platform	Target Indication	Development Stage
QXL138AM	Masked ImmunoCytokine	Multiple Myeloma	Preclinical
SLNP-IC1	Nammisome	Solid Tumors	Preclinical
NTI-121	Nammisome	Solid Tumors	Lead Optimization
NTI-205	Masked ImmunoCytokine	HER2+ Cancers	Candidate Selection
SLNP-PD1	Nammisome	Checkpoint Inhibitor Resistance	Early Discovery

Latest News

Press Release

Nammi Therapeutics Announces Preclinical Data for QXL138AM

Promising results demonstrate tumor-specific activation and reduced systemic toxicity in multiple myeloma models.

January 15, 2023

Company Update

Nammi Expands Nammisome Platform with New Combination Candidates

New formulations combining chemotherapy with immune agonists show synergistic anti-tumor activity in preclinical studies.

December 3, 2022

Get in Touch

For more information about Nammi Therapeutics and our innovative immuno-oncology platforms, please visit our official website.

Visit Official Website

Note: Please do not contact us regarding messages from domains other than "nammirx.com" as they are not originated from our company.